Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303

1.

Association of p53 mutations with metastatic prostate cancer.

Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC.

Clin Cancer Res. 1995 Oct;1(10):1111-8.

2.

p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.

Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ.

J Natl Cancer Inst. 1993 Oct 20;85(20):1657-69.

PMID:
7692074
3.

Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy.

Incognito LS, Cazares LH, Schellhammer PF, Kuban DA, Van Dyk EO, Moriarty RP, Wright GL Jr, Somers KD.

Int J Oncol. 2000 Oct;17(4):761-9.

PMID:
10995889
4.

p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.

Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N, McLeod DG, Moul JW, Srivastava S.

Prostate Cancer Prostatic Dis. 2003;6(4):281-5.

PMID:
14663467
5.

p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.

Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD.

J Natl Cancer Inst. 1997 Jan 15;89(2):158-65.

PMID:
8998185
6.

Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations.

Mottaz AE, Markwalder R, Fey MF, Klima I, Merz VW, Thalmann GN, Ball RK, Studer UE.

Prostate. 1997 Jun 1;31(4):209-15.

PMID:
9180930
7.

p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.

Bian YS, Osterheld MC, Bosman FT, Benhattar J, Fontolliet C.

Mod Pathol. 2001 May;14(5):397-403.

8.

Tumor suppressor gene p53 mutations in human prostate cancer.

Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, et al.

Prostate. 1995 Jul;27(1):18-24.

PMID:
7603913
9.

Clinical significance of p53 alterations in surgically treated prostate cancers.

Schlomm T, Iwers L, Kirstein P, Jessen B, K├Âllermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A.

Mod Pathol. 2008 Nov;21(11):1371-8. doi: 10.1038/modpathol.2008.104. Epub 2008 Jun 13.

10.

p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.

Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW.

J Natl Cancer Inst. 1997 Jan 1;89(1):66-71.

PMID:
8978408
11.

Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.

Rall CJ, Yan YX, Graeme-Cook F, Beauchamp R, Yandell DW, Povoski SP, Rustgi AK.

Pancreas. 1996 Jan;12(1):10-7.

PMID:
8927612
12.

Frequency and characterization of p53 mutations in clinically localized prostate cancer.

Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LW.

Urology. 1995 Mar;45(3):470-5.

PMID:
7879337
13.

Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.

Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW.

Cancer. 1998 Dec 15;83(12):2534-9.

PMID:
9874460
14.

p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.

Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ.

J Urol. 1999 Jan;161(1):304-8.

PMID:
10037428
15.

p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.

Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, Clarke S, Chapuis P, Solomon MJ.

Dis Colon Rectum. 2003 Feb;46(2):192-202.

PMID:
12576893
16.

Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases.

Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC.

Clin Cancer Res. 1997 Aug;3(8):1389-97.

17.

APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.

Hsieh JS, Lin SR, Chang MY, Chen FM, Lu CY, Huang TJ, Huang YS, Huang CJ, Wang JY.

Am Surg. 2005 Apr;71(4):336-43.

PMID:
15943410
18.

p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?

Cheng L, Leibovich BC, Bergstralh EJ, Scherer BG, Pacelli A, Ramnani DM, Zincke H, Bostwick DG.

Cancer. 1999 Jun 1;85(11):2455-9.

PMID:
10357418
19.
20.

P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.

Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S, Mizumoto S, Becker K, Dittler HJ, Fink U, Siewert JR.

Clin Cancer Res. 2000 Aug;6(8):3153-8.

Supplemental Content

Support Center